Summary
Unable to assess label alignment because the prompt does not provide a concrete AI-generated prescribing/label-comparison response to evaluate; only a list of general statements is provided without mapping to exact label claims. Therefore, support/contradiction/omission cannot be determined against the supplied label excerpts.
Category Scores
Accurate Statements
Unsupported Statements
Pregabalin is a prescription medicine for conditions such as neuropathic pain and certain seizure disorders.
Not verifiable as supported/accurate vs the supplied label excerpts because the evaluation input does not provide an exact AI response sentence to map to a specific label statement (and the label excerpt for indications lists neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, plus an efficacy statement for partial onset seizures).
There is no reliable evidence that any food supplement can replace pregabalin.
No supporting or relevant contraindication/warning/statement about 'food supplements replacing pregabalin' is present in the provided label excerpts.
Pregabalin can cause drowsiness.
A similar risk is included in the label ('dizziness and somnolence'), but direct support cannot be confirmed because the item is not evaluated within a concrete, labeled claim-response pair.
Pregabalin can cause dizziness.
The label includes 'dizziness and somnolence,' but direct support cannot be confirmed within the provided evaluation framework.
Pregabalin can cause coordination problems.
No 'coordination problems' statement is present in the provided excerpts.
Supplements that also cause sedation or affect the nervous system could increase pregabalin side effects.
The label discusses CNS depressants/opioids and monitoring, but does not support claims about 'supplements' increasing side effects.
Sedating herbal products used for sleep or relaxation raise concerns for increased sedation or nervous system effects when used with pregabalin.
No 'herbal products' or 'sleep/relaxation herbs' interaction language appears in the provided excerpts.
Alcohol and cannabis can be commonly combined with sedating effects that may increase pregabalin side effects.
The provided excerpts discuss 'CNS depressants, including opioids' but do not mention alcohol or cannabis.
Even natural products can interact with pregabalin.
The label excerpt addresses general PK interaction potential and that interactions are not systematically evaluated; it does not support a broad 'natural products' statement.
Clinicians advise caution with anything marketed as a sedative/sleep aid in people taking pregabalin.
The label includes monitoring/starting low when co-prescribing with another CNS depressant, but does not support the broader 'marketed as sedative/sleep aid' phrasing.
Clinicians advise caution with high-dose products without clear dosing and quality testing in people taking pregabalin.
No label excerpt addresses dosing quality/testing of supplements.
Clinicians advise caution with multiple supplements taken together that can compound drowsiness in people taking pregabalin.
No label excerpt supports supplement-specific advice about compounding drowsiness.
Avoid starting new supplements to match the effect of pregabalin without medical input.
No label excerpt addresses supplement initiation to 'match the effect' of pregabalin.
Kidney problems are important for pregabalin dosing.
Label excerpt supports renal impairment guidance, but direct support cannot be confirmed in the provided evaluation framework.
Contradictions
Important Omissions
Specific FDA label-aligned statements would be required to evaluate dosage/administration, maximum dosing, renal impairment thresholds, contraindications (hypersensitivity), and key warnings (e.g., respiratory depression monitoring, suicidal behavior risk).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided statements are largely general and non-prescriptive; however, several supplement/alcohol/cannabis interaction claims are not supported by the provided label excerpts, preventing a robust on-label safety alignment assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Assessable as Label-Aligned
Primary Issue
No single, exact AI-generated response text was provided in a form that can be reliably mapped to the supplied FDA label excerpts; multiple statements (especially supplement/herbal/alcohol/cannabis interactions) are unsupported by the provided label text.
Suggested Improvement
Provide the exact one-sentence (or complete) AI response to evaluate, and restrict claims to those explicitly present in the provided prescribing-information excerpts (e.g., CNS depressants/respiratory depression monitoring; dizziness/somnolence).